Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
20072 | 413 | 39.9 | 77% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
2118 | 4652 | BINUCLEATED LYMPHOCYTES//HUMANIZED MICE//CHEMOSENSITIVITY TEST |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | FP3 | Author keyword | 15 | 88% | 2% | 7 |
2 | HOLLOW FIBRE ASSAY | Author keyword | 4 | 75% | 1% | 3 |
3 | AFFILIATED ZHUJI HOSP | Address | 3 | 43% | 1% | 6 |
4 | ZHEJIANG CANC HOSP | Address | 3 | 45% | 1% | 5 |
5 | PATIENT DERIVED XENOGRAFT | Author keyword | 2 | 33% | 1% | 5 |
6 | ANTIANGIOGENIC EFFECT | Author keyword | 2 | 31% | 1% | 5 |
7 | PATIENT DERIVED XENOGRAFTS | Author keyword | 2 | 31% | 1% | 5 |
8 | TUMORGRAFT | Author keyword | 1 | 50% | 0% | 2 |
9 | TUMORGRAFTS | Author keyword | 1 | 33% | 1% | 3 |
10 | LIVING TUMOR | Address | 1 | 40% | 0% | 2 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | FP3 | 15 | 88% | 2% | 7 | Search FP3 | Search FP3 |
2 | HOLLOW FIBRE ASSAY | 4 | 75% | 1% | 3 | Search HOLLOW+FIBRE+ASSAY | Search HOLLOW+FIBRE+ASSAY |
3 | PATIENT DERIVED XENOGRAFT | 2 | 33% | 1% | 5 | Search PATIENT+DERIVED+XENOGRAFT | Search PATIENT+DERIVED+XENOGRAFT |
4 | ANTIANGIOGENIC EFFECT | 2 | 31% | 1% | 5 | Search ANTIANGIOGENIC+EFFECT | Search ANTIANGIOGENIC+EFFECT |
5 | PATIENT DERIVED XENOGRAFTS | 2 | 31% | 1% | 5 | Search PATIENT+DERIVED+XENOGRAFTS | Search PATIENT+DERIVED+XENOGRAFTS |
6 | TUMORGRAFT | 1 | 50% | 0% | 2 | Search TUMORGRAFT | Search TUMORGRAFT |
7 | TUMORGRAFTS | 1 | 33% | 1% | 3 | Search TUMORGRAFTS | Search TUMORGRAFTS |
8 | HOLLOW FIBER ASSAY | 1 | 25% | 1% | 3 | Search HOLLOW+FIBER+ASSAY | Search HOLLOW+FIBER+ASSAY |
9 | GENETICALLY ENGINEERED MOUSE MODELS | 1 | 17% | 1% | 4 | Search GENETICALLY+ENGINEERED+MOUSE+MODELS | Search GENETICALLY+ENGINEERED+MOUSE+MODELS |
10 | PDX | 1 | 17% | 1% | 4 | Search PDX | Search PDX |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TERM SERIAL TRANSPLANTATION | 9 | 83% | 1% | 5 |
2 | SUBRENAL CAPSULE XENOGRAFTS | 3 | 45% | 1% | 5 |
3 | ENGINEERED MOUSE MODELS | 2 | 15% | 2% | 10 |
4 | LARGE PANEL | 1 | 50% | 0% | 2 |
5 | LUNG CANCER XENOGRAFTS | 1 | 50% | 0% | 2 |
6 | MATCHED DISTANT METASTASES | 1 | 50% | 0% | 2 |
7 | PANCREATIC CANCER XENOGRAFTS | 1 | 50% | 0% | 2 |
8 | VEGF BLOCKER | 1 | 100% | 0% | 2 |
9 | ANTICANCER DRUG DEVELOPMENT | 1 | 15% | 2% | 7 |
10 | HOLLOW FIBER ASSAY | 1 | 30% | 1% | 3 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Patient-derived tumour xenografts as models for oncology drug development | 2012 | 142 | 106 | 34% |
One mouse, one patient paradigm: New avatars of personalized cancer therapy | 2014 | 24 | 75 | 32% |
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research | 2014 | 18 | 70 | 34% |
Prioritizing therapeutic targets using patient-derived xenograft models | 2015 | 2 | 109 | 23% |
Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery | 2014 | 24 | 64 | 20% |
Patient-derived xenograft models of breast cancer and their predictive power | 2015 | 1 | 73 | 29% |
Contributions of human tumor xenografts to anticancer drug development | 2006 | 139 | 15 | 47% |
Cancer Cell Lines for Drug Discovery and Development | 2014 | 12 | 38 | 24% |
Patient-derived breast tumor xenografts facilitating personalized cancer therapy | 2013 | 19 | 45 | 31% |
Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes | 2012 | 30 | 42 | 29% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | AFFILIATED ZHUJI HOSP | 3 | 43% | 1.5% | 6 |
2 | ZHEJIANG CANC HOSP | 3 | 45% | 1.2% | 5 |
3 | LIVING TUMOR | 1 | 40% | 0.5% | 2 |
4 | AFFYMETRIX PLATFORM | 1 | 50% | 0.2% | 1 |
5 | BIOCONJUGATE DISCOVERY DEV | 1 | 50% | 0.2% | 1 |
6 | BIOINFORMAT COMPUTAT SCI | 1 | 50% | 0.2% | 1 |
7 | CANC IMMUNOGENET ONCOL | 1 | 50% | 0.2% | 1 |
8 | CLIN EXPT ANIM | 1 | 50% | 0.2% | 1 |
9 | COMPREHENS CANC CLIN CANC | 1 | 50% | 0.2% | 1 |
10 | DATA ECT STAT RISK ASSESSMENT | 1 | 50% | 0.2% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000203241 | SURGICAL ORTHOTOPIC IMPLANTATION//ORTHOTOPIC IMPLANTATION//ORTHOTOPIC MOUSE MODELS |
2 | 0.0000132784 | TRANSPLACENTAL MUTAGENICITY//ANTITUMOR PREPARATIONS//CANA3DTPA |
3 | 0.0000123409 | BUCCAL DRUG ABSORPTION//HUMAN ENDOMETRIAL ADENOCARCINOMA//BIOL CHEM ERNAHRUNGSWISSEN AFT |
4 | 0.0000122714 | GIRENTUXIMAB//G250//MONOCLONAL ANTIBODY CG250 |
5 | 0.0000120692 | CHEMOSENSITIVITY TEST//HISTOCULTURE DRUG RESPONSE ASSAY//CD DST |
6 | 0.0000111708 | HUMANIZED MICE//HU PBL SCID//SCID MOUSE |
7 | 0.0000104149 | LY573636//TASISULAM//NCI 60 |
8 | 0.0000080170 | KRN5500//SPICAMYCIN//FUNCT PAIN NEUROIMAGING THER Y |
9 | 0.0000078657 | EVOLUT CANC//PETOS PARADOX//TRANSLAT CANC THER EUT |
10 | 0.0000068766 | ALKALINE TIDE//HUMAN OSCC//IN VIVO ENVIRONMENT |